A renowned clinician-scientist, Professor Albert Frauman’s research has focused on autoimmunity, viral infection and biomarkers of cancer progression. Now Director and CEO of Esfam Biotech, he has a long-standing interest in biomarkers as diagnostics and drug targets, and experience in the design, conduct and analysis of Phase I, II and III studies.

Professor Frauman is trained in Clinical Pharmacology and Endocrinology and completed his research doctorate at the University of Melbourne, where he researched the pharmacokinetics of alternative insulin formulations in diabetes. He later completed postdoctoral research on the cell and molecular biology of the thyroid at Harvard Medical School and the Walter and Eliza Hall Institute.

With over 70 peer-reviewed research publications, Professor Frauman ’s career highlights include serving as Medical Director of a phase 1 clinical trials facility, Nucleus Network and investigator on large Program Grants from the Victorian Government, Victoria Cancer Agency and Australian Cancer Research Foundation. He has been a Professorial Fellow at the Baker IDI Institute and a member of the Editorial Boards for the British Journal of Clinical Pharmacology, American Journal of Pharmacogenomics, Molecular Diagnosis and Therapy, and the Oncology Times.


Managing Director & Chair

As Co-founder of Esfam Biotech, Liz Ferentinos brings her passion for transforming companies to be the best they can be. Having started her first business in Greece at 18, Ferentinos has time and again demonstrated strong commercial and relational sense. She prides herself on identifying opportunities and pulling together the right team to achieve them.

Ferentinos brings more than 30 years of entrepreneurial experience to Esfam Biotech, including in corporate governance, capital allocation, portfolio management, and mergers and acquisitions. As Managing Director and Co-Founder, Ferentinos’s diverse skills also cover e-commerce, fundraising, project direction and financial management. She is also Co-founder and CEO of Meizon Innovation in developing early diagnostics and therapeutics for Dementia including Alzheimer’s disease to people in times of significant vulnerability.

An active supporter of children’s wellbeing and social justice, Ferentinos is a board member of Creative Art Therapy Australia and a volunteer for organisations including Koala Kids (Kids Oncology and Leukemia Action), Shine and The Longest Night Appeal. Relationship building has been critical to every part of her career, from hand-selecting investors to bringing hope to families who have had none.



Sergio Duchini has 23 years experience as a senior tax partner in Global Investment and Innovation Incentives (Gi3), Deloitte’s pre-eminent global R&D advisory practice. He is passionate about the success of the Australian biotech industry, serving as a Board member of Ausbiotech since 2014 and actively involved in advising and working with participants and government, specialising in tax incentives, structuring and industry assistance programs, his 30+ year career has seen him work with blue-chip clients including CSL, Cochlear, Rio Tinto, ANZ, NAB, Jemena and Australia Post.

Duchini has extensive life science, corporate governance experience and commercial experience. He is currently Chairman of Lymphoma Australia and a Director of Ausbiotech. He served for 7 years as a member of the Deloitte Australia Board, with 3 years as Chair of the Partner Remuneration Committee.


PhD BSc (Hons) LLB
Intellectual Property Advisor

Neil Ireland is a partner in the Chemistry and Life Sciences practice group, with 23 years of patenting experience across a wide range of chemical technologies. His particular expertise is in the protection of small molecules in the pharmaceutical area, making him an ideal advisor on Esfam Biotech’s revolutionary developments.

Ireland is deeply embedded in this sector. He is a judge of the BHP Foundation science and engineering awards, a partnership between BHP Foundation, CSIRO and the Australian Science Teacher’s Assocation. Completing his PhD in Chemistry at University of Melbourne in 1994, he the co-author of six research publications and was awarded the Institute Prize by the Institute of Patent and Trade Marks Attorneys of Australia for high academic achievement.


Bbus Mktg
Advisory Board Member

Kimberlee Wells is CEO of TBWA, a global advertising agency headquartered in NYC. As a professional disrupter, she has advised many of Australia’s leading brands and government agencies, leveraging creativity as an accelerant for shareholder value and driving positive social change.

Having held senior roles at several major agencies, including Clemenger Proximity and George Patterson Y&R, Wells is considered among B&T’s top 10 most powerful women in Australian media and an inspiring leader within the industry. She is currently one of only 30 global creative leaders advising Google Assembly on the role of creativity and technology in our social future.


BComm GradDipBus(ProfAcc) GradDipBus(AppFin)
Advisory Board Member

Adrian Hondros has applied his strong communication and consultative work to over 30 years of leadership experience in the Australian financial services sector. He is now CEO of Porter Davis, where he leads his executive team in the execution of a bold strategic plan focused on sustainable growth and consumer recognition.

Hondros’s specialised board experience began with his first directorship in 1997. Since then, he has served on numerous financial services Boards including as Chair of the Commonwealth Private Limited Board, a Trustee Director of the Commonwealth Bank’s Group Super Board and Chair of its Investment Committee. In 2017 he was appointment as an independent director of the Commonwealth Bank’s Private Health Insurance Fund, CBHS.


LLM LLB (Hons) BComm (Hons)
Advisory Board Member

Jonathan Farrer is a partner at Corrs Chambers Wesgarth, one of Australia’s top law firms. Having lead the national startups practice at Corrs, he brings to Esfam Biotech a specialist commercial perspective with a focus on M&A, strategic advice, corporate governance and capital raisings. He was a key advisor on Esfam’s spin-out from the University of Melbourne.

Farrer has worked on more than 100 transactions with a combined value of over $50 billion, and has been ranked as one of Australia’s top 10 M&A dealmakers. He is a lecturer at the University of Melbourne and co-editor of the takeovers and public securities section of the Companies and Securities Law Journal.


PhD BE (Hons)

Hank Sciberras is a Partner in the EY Innovation and Incentives team assisting companies with commercialisation planning and strategies for their technologies as well as gaining non-dilutive funding. He has more than 20 years of experience in assisting Australia’s largest companies as well as start-ups. Prior to joining EY, Sciberras led the life science team for Deloitte in Australia, has worked in a number of countries developing deep ultraviolet laser technology for eye surgery, and the semiconductor industry.


Kostas Kyrifidis currently leads the enterprise risk portfolio within ESFAM Biotech. Kostas is an accomplished corporate governance, risk, project management, asset protection, safety and environment professional who brings over 30 years of experience in the government, commercial, industrial facilities and professional services sectors.

Along with being a Board Member/Strategic Advisor to a number of Commercial, NFP Boards and Executive Leadership Teams, Kostas provides coaching and development to support organisations with implementing programs to set clear strategic goals, innovation, protective security, cyber hygiene, risk minimisation and utilisation of resources.



Sharon Lewin is the inaugural director of the Peter Doherty Institute for Infection and Immunity, a joint venture between the University of Melbourne and Royal Melbourne Hospital; Melbourne Laureate Professor, The University of Melbourne; consultant infectious diseases physician, Alfred Hospital and Royal Melbourne Hospital and a National Health and Medical Research Council (NHMRC) Practitioner Fellow.

She is an infectious diseases physician and basic scientist. She completed her medical degree and PhD in virology at Monash University in 1996 and her post-doctoral fellowship with Dr David Ho at Rockefeller University in 1999. Her research focuses on understanding why HIV persists on treatment and developing clinical trials aimed at ultimately finding a cure for HIV infection. She has published over 300 publications and given over 100 major invited talks on HIV cure. She has received multiple national and international awards for her HIV-related research and community engagement. In 2014 she was named Melburnian of the Year and in 2019 was named a Clarivate Web of Science high citation researcher. She is President-Elect of the International AIDS Society.

She leads a large national network funded by the National Health and Medical Research Council of Australia called The Australian Partnership in Research for Infectious Disease Emergencies (APPRISE) which focuses on pandemic preparedness and started in Australia in 2016. Scientists from the Doherty Institute were the first to isolate and share the SARS COV2 virus outside of China and have a broad program of research focused on testing, treatments and vaccines for COVID19.